In Brief Mount Sinai mammography van intended to break down disparities in screening October 26, 2018Vol.44 No.40
Trump’s drug pricing plan pegs Medicare Part B payments to international levels October 26, 2018Vol.44 No.40By Paul Goldberg
Has Tecentriq earned a role in treatment of triple-negative breast cancer?Here is what experts say October 26, 2018Vol.44 No.40
Conversation with The Cancer Letter NCI’s Korde: Follow-up needed to validate PFS with mature OS results for Tecentriq October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
Long-awaited trial of checkpoint inhibitor in breast cancerproduces 2-month PFS gain; no final OS advantage seen—yet October 26, 2018Vol.44 No.40By Matthew Bin Han Ong
Drugs & Targets Myriad’s test receives FDA approval as companion diagnostic for Pfizer’s Talzenna October 19, 2018Vol.44 No.39
Drugs & Targets Huge variations between countries in time for reimbursement decisions on new cancer drugs October 19, 2018Vol.44 No.39
Drugs & Targets AbbVie’s sNDA accepted for priority review for Imbruvica in combination with Gazyva for previously untreated CLL October 19, 2018Vol.44 No.39
Drugs & Targets The Parker Institute, Xyphos Biosciences developing universal programmable CAR-T cells October 19, 2018Vol.44 No.39
